Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Far-Red FRET biosensor for AMPK enables multiplexed imaging of single-cell bioenergetic homeostasis.

bioRxiv : the preprint server for biology·2026
Same author

Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.

Molecular cancer therapeutics·2026
Same author

Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.

Molecular cancer therapeutics·2026
Same author

Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.

Oncogene·2026
Same author

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

The Journal of clinical investigation·2026
Same author

A clinical-stage oncology compound selectively targets drug-resistant cancers.

bioRxiv : the preprint server for biology·2025
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

Bryan Correa Gonzalez1, Akshaya Karthikeyan1, Love A Moore1

  • 1Department of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.

Biomedicines
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

Combining PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) shows promise for advanced prostate cancer. ATM inhibition may offer superior efficacy over ARPi in ARPi-resistant models, suggesting new therapeutic strategies.

Keywords:
AR-pathway inhibitorATM inhibitorPARP inhibitorlartesertibprostate cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genitourinary Cancers

Background:

  • Advanced prostate cancer treatment benefits from combining PARP inhibitors (PARPi) and androgen receptor pathway inhibitors (ARPi).
  • The optimal clinical use and precise mechanisms of these drug combinations remain unclear.
  • Investigating alternative strategies to enhance PARPi effectiveness is crucial.

Purpose of the Study:

  • To clarify the clinical positioning and mechanisms of PARPi and ARPi combinations in prostate cancer.
  • To explore the efficacy of ATM inhibition in combination with PARPi.
  • To identify strategies for overcoming resistance to ARPi.

Main Methods:

  • Assessing cell viability and morphology in response to PARPi and ARPi combinations in castration-resistant and ARPi-resistant prostate cancer models.
  • Evaluating the efficacy of an ATM inhibitor (lartesertib) combined with a PARPi.
  • Utilizing Western blots and RNA-sequencing to investigate treatment mechanisms.

Main Results:

  • PARPi and ARPi combinations demonstrated effectiveness across all tested models, with greatest benefit observed in ARPi-sensitive cells.
  • ARPi did not alter homologous recombination repair gene expression but may elevate PARP activity.
  • PARP inhibition increased androgen receptor target gene expression and enhanced sensitivity to enzalutamide.
  • ATM inhibition significantly boosted PARPi efficacy, outperforming ARPi combinations in ARPi-resistant models.

Conclusions:

  • While PARPi and ARPi combinations are effective in ARPi-resistant prostate cancer, they show stronger efficacy in ARPi-sensitive settings.
  • PARP inhibition might enhance ARPi sensitivity through increased androgen receptor activity.
  • ATM inhibition presents a potential therapeutic advantage over ARPi in combination with PARPi for ARPi-resistant prostate cancer.
  • These findings support further development of PARPi for improved prostate cancer patient outcomes.